Creo Medical Group (CREO)

Sector:

Health Care

Index:

FTSE AIM All-Share

36.00p
   
  • Change Today:
    -0.25p
  • 52 Week High: 48.10p
  • 52 Week Low: 23.25p
  • Currency: UK Pounds
  • Shares Issued: 361.48m
  • Volume: 167,482
  • Market Cap: £130.13m

Creo Medical opens new US headquarters as it focuses on market

By Josh White

Date: Friday 16 Jul 2021

LONDON (ShareCast) - (Sharecast News) - Surgical endoscopy medical devices company Creo Medical Group has opened its United States headquarters at the Summit in Danbury, Connecticut, it announced on Friday.
The AIM-traded firm said the space was designed to support its global growth and focus in the "key" US market, with a learning centre and a fully-equipped laboratory for clinical development and training purposes, which it said would support its education-led commercialisation strategy.

US customer service, finance, product logistics, distribution and other day-to-day functions would also be based in the Danbury office.

Located north-east of New York City, Creo said the office's proximity to international airports provided "convenient access" for visiting clinicians and members of staff.

"We are delighted and proud to have opened our first United States facility, illustrating our commitment to growth and our focus on the key US market," said chief executive officer Craig Gulliford.

"These new premises will provide an excellent working environment for our US team and a platform to attract further talent in this key region of the US market."

Over the past 18 months, Creo had established a direct commercial team in the US, led by "experienced and successful" leaders in market development.

The company also had a US director of clinical education, assisted by clinical support specialists, responsible for ensuring safe and effective use of its product platform and devices.

Creo said its 'Croma' energy generator platform was in place at a number of academic institutions across the US, with key opinion leaders trained through its clinical education programme.

Those centres had treated their first patients in the US, and had been identified as 'centres of excellence' for the operation of the firm's clinical education programme.

They would be key training sites to educate the second wave of US clinical users, Creo explained, adding that it intended to increase the number of US installations and training centres to support the scaling of its presence in the country.

"Since my appointment in August last year, I have been busy assembling an experienced team to help capitalise on our continued evolution and expansion as a leading medical device company," said chief commercial officer David Woods.

"The opening of this clinical training and commercial support facility in the US represents the next phase in our planned and sustained development and further illustrates our growth and focus in the region, which gives even greater access to another important market."

At 1041 BST, shares in Creo Medical were up 0.28% at 181p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

CREO Market Data

Currency UK Pounds
Share Price 36.00p
Change Today -0.25p
% Change -0.69 %
52 Week High 48.10p
52 Week Low 23.25p
Volume 167,482
Shares Issued 361.48m
Market Cap £130.13m

CREO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
23.43% below the market average23.43% below the market average23.43% below the market average23.43% below the market average23.43% below the market average
35.48% below the sector average35.48% below the sector average35.48% below the sector average35.48% below the sector average35.48% below the sector average
Price Trend
13.89% above the market average13.89% above the market average13.89% above the market average13.89% above the market average13.89% above the market average
35.14% above the sector average35.14% above the sector average35.14% above the sector average35.14% above the sector average35.14% above the sector average
Income Not Available
Growth
42.70% above the market average42.70% above the market average42.70% above the market average42.70% above the market average42.70% above the market average
66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

CREO Dividends

No dividends found

Trades for 29-Apr-2024

Time Volume / Share Price
14:00 2,000 @ 36.00p
14:00 2,000 @ 36.00p
12:53 676 @ 36.34p
12:43 1,370 @ 36.47p
11:54 2,890 @ 36.00p

CREO Key Personnel

CEO Craig Jonathan Gulliford
CFO Richard John Rees

Top of Page